296 results about "Tumor vessel" patented technology

Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and CD40 ligand. In other methods, administration of a fusion protein containing the TVECA and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. Further methods comprise the combination therapy using an expression vector encoding a secretable TVECA fusion protein and a tumor antigen vaccine.

The invention discloses an application of metal fullerene monocrystal nanoparticles in preparation of a tumor vascular disrupting agent. The monocrystal nanoparticles are water-soluble metal fullerene nanoparticles with the surface charged with negative electricity, and have the particle size range of 50-250 nm; the nanomaterial can absorb and convert outside world radiation energy into heat energy, and the volume is expanded sharply when a temperature reaches a phase transition point. During treatment, a tumor-carried living organism is injected and given with the metal fullerene monocrystal nanoparticles; the metal fullerene monocrystal nanoparticles reach a tumor part through blood circulation, and are stranded at tumor pores and defective parts; under the action of the outside world radiation energy, the metal fullerene monocrystal nanoparticles accumulate heat, the temperature rises, and the volume is expanded sharply when the temperature exceeds the phase transformation critical point, so that morphological structures or functions of tumor vascular endothelial cells are changed, and tumor vessels are interdicted so as to make the tumor cells starved to death.

The invention relates to an anticancer slow-release gel injection which contains slow-release microspheres containing an angiogenesis inhibitor, an amphiphilic block polymer, a solvent and a slow-release agent, wherein the composition of the amphiphilic block polymer and the non-organic solvent exhibit the property of temperature-sensitive gelation. After the in vivo injection, the injection turns into a stagnant and biodegradable water-insoluble gel and the gel slowly releases the drug contained therein for a plurality of weeks to a plurality of months. After the intratumoral or peritumoral injection, the anticancer slow-release gel injection can significantly reduce the general drug reactions and is used for treating tumors of different stages. The angiogenesis inhibitor is selected from SU5416, SU6668, bosutinib, sprycel, erlotinib, vandetanib, gefitnib, canertinib, lapatinib, lestaurtinib, masitinib, vatalanib, mubritinib, tandutinib, nilotinib, marimastat, nilotinib, pelitinib, telatinib, sunitinib, sorafenib, zarnestra, sirolimus, imatinfb, lenalidomide and thalidomide.

The invention relates to a tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system, as well as a preparation method and application thereof. The tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system comprises mesoporous silica nano-particles, RGD polypeptide which is linked to the surfaces of the mesoporous silica nano-particles in a covalent manner and serves as a tumor vessel/tumor cell membrane targeting ligand, and a nuclear localization signal polypeptide sequence serving as a cell nucleus targeting ligand. Under the condition of intravenous injection, the drug-loaded system can be enriched in a tumor tissue by means of the targeting effect of the tumor vessel to reduce the uptake of normal tissues and reduce toxic and side effect, is capable of increasing the phagocytosis amount of tumor cells by means of the identification effect on the tumor cell membrane, and can be used for directly delivering anti-cancer drugs into a cell nucleus by means of the delivery performance of the cell nucleus to increase the concentration of effective drugs, so that an optimal treatment effect can be achieved.

A liver cancer blood vessel specific target polypeptide LCI-X7 able to specific binding with liver cancer blood vessel is extracted from the naked mouse model of human liver cancer by the showing technique of phage random peptide library in body and microscopic laser cutting technique. It provides important theory and practical basis for the diagnosis to liver cancer transfer recurrence and target therapy.

The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.

The invention discloses an ethoxydiphenylethane derivative and a synthetic method and uses thereof 4′ position of phenylethane B aromatic ring is chemically modified by ethoxy and hydroxy at position 3′ thereof is simultaneously modified to water soluble prodrug such as phosphate, and similarly, amino acid side chain is introduced to amino at position 3′ to form amino acid amide water soluble prodrug having the structure shown as formula (I)

the ethoxydiphenylethane derivative and the prodrug thereof include strong tubulin aggregation inhibiting ability and obvious target damage effect for tumor vessels, selectively cause dysfunction and structural damage of tumor vessels and induce apoptosis of vascular endothelial cells in order to play the role of killing tumor cells or inhibiting tumor metastasis in case that the tumor cells are free from the support of nutrition and oxygen.

The invention discloses an application of miltirone in preparation of antitumor drugs. The miltirone has a structure of formula I; the miltirone serves as an inhibitor of STAT3 (Signal Transducer and Activator of Transcription 3) and is capable of inhibiting growth and proliferation of tumor cells which are abnormally activated by STAT3 so as to cause the apoptosis of the tumor cells and also capable of improving sensibility of cytotoxic drugs and inhibiting formation of tumor vessels. The miltirone with the structure of formula I can inhibit STAT3 kinase Tyr705 phosphorylation level to achieve the functions of accelerating the apoptosis of the tumor cells, improving the sensibility of chemotherapy drugs and inhibiting formation of new vessels; and the proliferation of tumor cells can be significantly inhibited due to the combined combination of the miltirone with low toxicity or non-toxic concentration and adriacin doxorubicin with low toxicity or non-toxic concentration and the combined application of the miltirone and cis-platinum with low toxicity or non-toxic concentration. The functions of the miltirone with the structure of formula I have positive significance to prevention and treatment of tumors.

The invention discloses a magnetic resonance imaging detectable in-situ liquid crystal precursor embolism composition which comprises the following components: an MRI water-soluble or water-insoluble contrast medium, a liquid crystal material, a physiological acceptable water-soluble organic solvent and water. The following components can be added according to the treatment goal and the clinical demand: an X ray-impermeable water-soluble or water-insoluble contrast medium and/or drugs. The MRI detectable liquid embolism composition disclosed by the invention has the characteristics of low viscosity, no toxicity, low cost and fast curing, can be injected, and is mainly used in local embolism treatment and relevant imageological examination of tumors, vascular malformation and hemostasis.

The invention discloses a human single chain antibody and application of an antitumor vascular endothelium marker molecule 8-cell outer region. The amino acid sequence of the single chain antibody is SEQ ID NO:1. The amino acid sequence of a heavy chain variable region of the antibody is SEQ ID NO:2, and the amino acid sequence of a light chain variable region of the antibody is SEQ ID NO:3. The human single chain antibody of the antitumor vascular endothelium marker molecule 8-cell outer region can be applied to early diagnosis and target treatment of tumor.

The invention discloses a multi-parameter tumor blood vessel normalization detection system and detection method. The system comprises a light source module, an imaging module, a blood flow detectionand analysis module, a blood oxygen detection and analysis module, a blood vessel normalization judgment module and a display module. According to the method, a two-dimensional blood flow image is reconstructed through an algorithm, blood vessel morphology characteristics are extracted through an image processing method, a two-dimensional tumor blood oxygen image is calculated through a laser image and a narrow-band green light image, tumor tissue hypoxia degree information is provided, and through a deep neural network discrimination method and combination with blood flow image characteristics and blood oxygen image characteristics whether tumor vessels are normalized or not can be judged. The method has the advantages of being multi-parameter, non-invasive, non-radiative, intelligent indiagnosis and the like, whether tumor blood vessels are in a normal window period or not is intelligently judged by monitoring tumor blood supply, oxygen supply and blood vessel forms, and a basis isprovided for making a more reasonable anti-tumor combined treatment scheme.

The invention relates to a co-culture model of microencapsulated tumor cells and endothelial cells. The preparation method comprises the steps: first, tumor cells are mixed into 2 percent of sodium alginate solution to lead cells suspension which is injected with 100mmol/L of calcium chloride solution to be colloidized through a microcapsule generator then; normal saline is used for washing the obtained material which then reacts with 0.1 percent of polylysine solution and is washed by normal saline; next, 0.15 percent of sodium alginate solution is added and washed by normal saline; the 55mmol/L sodium citrate solution is employed to liquefy microcapsule core and cultured in a CO₂ of culture box; the microencapsulated tumor cells are directly used for being cultured or frozen reserved; the endothelial cells are employed to be adherently cultured or led to three dimensional growth; the microencapsulated tumor cells are added into the same culture solution; co-culture is done; tumor cells and endothelial cells are separated; finally, travelling gene detection, protein detection and culture liquid cytokine detection are done. The invention overcomes the limitation of Matrigel method and the defect of Transwell method, has an imitated micro-environment for microencapsulated tumor cells and endothelial cells to interact, and has long service life for one-time making and decreases research personnel and financial resources.

The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.

The invention provides the expression and the purification of a recombinant fusion protein, particularly a fusion protein of the tumor blood vessel targeted polypeptide and tissue factor and a preparation method and application thereof. The preparation method of the fusion protein of the tumor blood vessel targeted polypeptide and tissue factor comprises the following steps: designing primers, carrying out PCR (polymerase chain reaction) to amplify an recombinant gene of the fusion protein EG3287-tTF, guiding the recombinant gene of the fusion protein EG3287-tTF into a carrier, guiding a recombinant carrier into a host cell, constructing a recombinant engineering bacteria for expressing the fusion protein EG3287-tTF, fermenting to culture, and separating and purifying fermentation liquor to obtain the fusion protein of the tumor blood vessel targeted polypeptide and tissue factor. The targeted antitumor fusion protein EG3287-tTF is constructed, a novel tTF derivative with the antitumor advantage of the tTF and the targeting effect is obtained, the antitumor effect of the tTF is improved, and a foundation is laid to the development of a novel medicament for the targeted therapy of the tumor blood vessel.

The invention belongs to the fields of radiopharmaceuticals and nuclear medicine and provides an imaging drug <68>Ga-NOTA-IF7 targeting Anxa1 in tumor blood vessels and a preparation method thereof. The drug <68>Ga-NOTA-IF7 is used for differential diagnosis and periodization of tumors, accurate positioning of focuses and curative effect monitoring. According to the invention, the tumor imaging drug <68>Ga-NOTA-IF7 is prepared through leaching of <68>Ga and <68>Ga-NOTA-IF7 labeling. The preparation method has the advantages of simple preparation technology, convenient operation, small consumption of time, a high labeling rate and a stable marker and facilitates further application of the drug in clinical practice, scientific research and medicinal development. The invention also provides a novel positive electron tumor imaging agent. The novel positive electron tumor imaging agent has good targeting to tumors, so tumor imaging effects are improved, and a visual tool is provided for differential diagnosis and periodization of tumors, accurate positioning of focuses and curative effect monitoring. <68>Ga-NOTA-IF7 is a labeled compound belonging to polypeptide and has the advantages of small molecular weight, low immunogenicity, good tissue penetrability, high tumor tissue affinity and good application prospects.

The present invention includes a method and apparatus for tumor blood vessel obstruction and tumor therapy. The embolic device is made of biocompatible materials. The embolic device may utilize thrombus-enhancing filamentary material and/or coagulate components that enhance the effectiveness to cause tumor vasculature thrombosis. The specific design of the device will facilitate tumor vasculature site space-filling. The embolic device may be implanted into the targeted tumor vasculature site by minimal invasive method.

The invention discloses an antihuman Endoglin single-chain antibody, with the amino acid sequence shown as SEQ ID No.2, also discloses coded genes of the antihuman Endoglin single-chain antibody, a recombination carrier containing the coded genes, a transformant containing the recombination carrier and a radionuclide maker of the antibody Endoglin single-chain antibody, as well as discloses a preparation method of the antihuman Endoglin single-chain antibody, including such two steps as solubility expression and purification. The method is simple and easy to be operated, the stability of product is good and the purity is high. The research result shows that the antihuman Endoglin scFv is characterized by small molecular weight, strong penetration, low heterology, fast removal in vivo, shortage of Fc segments and the like, has excellent affinity and stability of the antigen, can be used as a guiding carrier of target-direction tumor vessel endothelium, and is used for the preparation of tumor diagnosis reagents and immunization therapy medicaments, thus having promising application prospect.

The invention discloses 11 sections special associative cyclic peptide GX of tumor veins of human alimentary canal. The invention makes use of the human transferred tumor model under the random phage cricoid 7-peptide and immunosuppression mouse nephridial envelope and screens the cricoid 7 peptide GX1-GX11 which can combine with the high specificity of human oesophagus cancer and human adenocarcinoma of stomach with poor differentiation. The competitive inhibition experiments among the plaque titration of the transplanted tumors' tissue, transplanting the tumors' tissue and the tissues of human cancer of stomach and esophageal carcinoma, GX1 compound peptide and GX1 present phage all show the specificity of the association of the 7-peptide with the tumor tissue of human alimentary canal. After sequencing, we can affirm the uniqueness of the protein sequence. These polypeptide sequences have great potential in the targeting treatment of tumor veins and the development of the symbol reagent of the specific molecule of the tumor veins.